Doksorubisin kardiyotoksisitesinde p38 map kinaz inhibitörünün moleküler genetik ve biyokimyasal parametrelere etkisi
Yükleniyor...
Dosyalar
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Sıçanlarda doksorubisin ile oluşturulan kardiyotoksisite modelinde p38 MAPK inhibitörü uygulamasının kalp dokusunda moleküler genetik ve biyokimyasal parametrelere olan etkisi. Materyal ve Metot: 48 adet Wistar albino cinsi erkek sıçan, her grupta 12 adet olmak üzere; K, DOX, p38 MAPKi, DOX+p38 MAPKi olarak 4 gruba ayrıldılar. Sıçanların kalp dokusundan SOD, MDA, GSH, CAT düzeyleri spektrofotometrik yöntemlerle, Kav-3, MMP-2, UCP-2, Kavin-4 genlerinin ifadeleri gerçek zamanlı-PZT analiziyle yapıldı. Sıçanlara kalp fonksiyon testleri uygulandı. Kalp dokularından hemotoksilen-eozin boyaması ile histopatolojik incelemeler yapıldı. Bulgular: DOX grubu MMP-2 gen ifadesi, K ve p38 MAPKi grubuna göre yükselmişti (p < 0.05). DOX, p38 MAPKi, DOX+p38 MAPKi grupları UCP-2 gen ifadeleri K grubuna göre artmıştı (p < 0.05). K ve p38 MAPKi grubuna göre, yükselen bir doku CAT aktivitesi DOX ve DOX+p38 MAPKi grubunda gözlendi (p < 0.05). DOX grubu MDA seviyesi K, p38 MAPKi ve DOX+p38 MAPKi gruplarına göre artmıştı (p < 0.05). DOX, p38 MAPKi ve DOX+p38 MAPKi gruplarında, K grubu ile karşılaştırıldığında artan bir SOD aktivitesi tespit edildi (p < 0.05). Histopatolojik olarak DOX grubunda görülen konjesyon-hemoraji ve dejenere kardiyomiyosit yoğunluğu K ve p38 MAPKi gruplarına göre anlamlı idi (p < 0.05). Sonuç: Doksorubisin sonrası p38 MAPK inhibitörü uygulamasının kalp dokusunda bazı mekanizmalar üzerinden kalp hasarının korunmasında koruyucu bir etki sağlayabileceğini düşünmekteyiz. Anahtar Kelimeler: MMP-2, Kaveolin-3, Kavin-4, p38 MAPK, kardiyotoksisite
Aim: The effects of p38 MAPK inhibitor application on molecular genetic and biochemical parameters in doxorubicin induced cardiotoxicity model in rats. Material and Method: 48 male Wistar albino rats were divided into 4 groups each containing 12 rats per group; The p38 MAPKi, DOX, C, DOX + p38 MAPKi group. In the heart tissue, expressions of Kav-3, MMP-2, UCP-2, Kavin-4 genes were performed by real-time PCR, while analysis of SOD, MDA, GSH, CAT levels were determined spectrophotometrically. Heart function tests were applied to rats. Histopathological examinations in the heart tissue were performed with hemotoxylin-eosin staining. Results: DOX group MMP-2 gene expression was increased compared to C and p38 MAPKi group. It was found that UCP-2 gene expression in DOX, p38 MAPKi, DOX + p38 MAPKi groups increased compared to the K group (p < 0.05). UCP-2 gene expression in DOX + p38 MAPKi group showed a decrease compared to the DOX group (p < 0.05). There was a statistically significant increase in tissue CAT activity in the DOX and DOX + p38 MAPKi group compared to the C and p38 MAPKi group (p < 0.05). Elevated MDA level in the DOX group was found to be significant compared to the C, p38 MAPKi and DOX + p38 MAPKi groups(p < 0.05). Increased SOD activity in DOX, p38 MAPKi and DOX + p38 MAPKi groups was found to be significant compared to the C group (p < 0.05). Histopathologically, congestion-hemorrhage anad degenerated cardiomyocyte density in the DOX group were found to be statistically higher than the C and p38 MAPKi groups (p < 0.05). Conclusion: We consider that the administration of p38 MAPK inhibitor after doxorubicin may provide a protective effect in the protection of heart damage on some mechanisms in the heart tissue. Key Words: MMP-2, Caveolin-3, Cavin-4, p38 MAPK, cardiotoxicity
Aim: The effects of p38 MAPK inhibitor application on molecular genetic and biochemical parameters in doxorubicin induced cardiotoxicity model in rats. Material and Method: 48 male Wistar albino rats were divided into 4 groups each containing 12 rats per group; The p38 MAPKi, DOX, C, DOX + p38 MAPKi group. In the heart tissue, expressions of Kav-3, MMP-2, UCP-2, Kavin-4 genes were performed by real-time PCR, while analysis of SOD, MDA, GSH, CAT levels were determined spectrophotometrically. Heart function tests were applied to rats. Histopathological examinations in the heart tissue were performed with hemotoxylin-eosin staining. Results: DOX group MMP-2 gene expression was increased compared to C and p38 MAPKi group. It was found that UCP-2 gene expression in DOX, p38 MAPKi, DOX + p38 MAPKi groups increased compared to the K group (p < 0.05). UCP-2 gene expression in DOX + p38 MAPKi group showed a decrease compared to the DOX group (p < 0.05). There was a statistically significant increase in tissue CAT activity in the DOX and DOX + p38 MAPKi group compared to the C and p38 MAPKi group (p < 0.05). Elevated MDA level in the DOX group was found to be significant compared to the C, p38 MAPKi and DOX + p38 MAPKi groups(p < 0.05). Increased SOD activity in DOX, p38 MAPKi and DOX + p38 MAPKi groups was found to be significant compared to the C group (p < 0.05). Histopathologically, congestion-hemorrhage anad degenerated cardiomyocyte density in the DOX group were found to be statistically higher than the C and p38 MAPKi groups (p < 0.05). Conclusion: We consider that the administration of p38 MAPK inhibitor after doxorubicin may provide a protective effect in the protection of heart damage on some mechanisms in the heart tissue. Key Words: MMP-2, Caveolin-3, Cavin-4, p38 MAPK, cardiotoxicity
Açıklama
Anahtar Kelimeler
Genetik, Genetics, Tıbbi Biyoloji, Medical Biology
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Özyazgan, B. (2021). Doksorubisin kardiyotoksisitesinde p38 map kinaz inhibitörünün moleküler genetik ve biyokimyasal parametrelere etkisi. Yayınlanmış Doktora Tezi, İnönü Üniversitesi.
